Background. In Syria, CML patients are started on tyrosine kinase inhibitors (TKIs) and monitored until complete molecular response is achieved. BCR-ABL mRNA transcript type is not routinely identified, contrary to the recommendations. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.